BACKGROUND: The aim of this study was to compare rate of onset, magnitude, and
consistency of platelet inhibition after administration of prasugrel or clopidogrel and to relate …

Prasugrel pharmacodynamics and pharmacokinetics after a 60-mg loading dose (LD) and
daily 10-mg maintenance doses (MD) were compared in a 3-way crossover study to …

Background and methods: Prasugrel is a novel orally active thienopyridine prodrug with
potent and long‐lasting antiplatelet effects. Platelet inhibition reflects inhibition of P2Y 12 …

Aims This study was designed to compare the degree of inhibition of platelet aggregation
(IPA) of prasugrel with that of clopidogrel in stable aspirin-treated patients with coronary …

Compared with the approved dose regimen of clopidogrel (300-mg loading dose [LD], 75-
mg maintenance dose [MD]), prasugrel has been demonstrated to reduce ischaemic events …

Background—The increasing use of higher-than-approved doses of clopidogrel in clinical
practice is based in part on the desire for greater levels of inhibition of platelet aggregation …

Aims P2Y 12 receptor antagonism and platelet inhibition by prasugrel vs. clopidogrel were
investigated in patients with stable coronary artery disease. Methods and results One …

Prasugrel, a novel P2Y 12 ADP-receptor antagonist, has been reported to achieve greater
inhibition of platelet aggregation compared to clopidogrel as assessed by light transmission …

Aims To examine the extent of platelet inhibition by prasugrel vs. clopidogrel in a TRITON-
TIMI 38 substudy. Methods and results TRITON-TIMI 38 randomized acute coronary …

Aims This double‐blind, placebo‐controlled trial was designed to evaluate the
pharmacodynamics, pharmacokinetics, safety, and tolerability of prasugrel (CS‐747 …